LeonaBio, Inc. Cash Flow Conversion Efficiency
LeonaBio, Inc. cash flow conversion efficiency. Based on the latest financial reports, LeonaBio, Inc. (LONA) has a cash flow conversion efficiency ratio of -0.424x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.90 Million) by net assets ($49.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of LeonaBio, Inc. (2018–2025)
Cash flow conversion efficiency of LeonaBio, Inc. from 2018 to 2025. This chart illustrates how LeonaBio, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of LeonaBio, Inc. for real-time trading data and today's change.
LeonaBio, Inc. Cash Flow Conversion Ratio Explained
LeonaBio, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
LeonaBio, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LeonaBio, Inc. ranked by their cash flow conversion efficiency. Also see LeonaBio, Inc. (LONA) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tunas Alfin Tbk
JK:TALF
|
0.034x |
|
Baltic Sea Properties AS
OL:BALT
|
0.027x |
|
IGLOO SECURITY Inc
KQ:067920
|
-0.005x |
|
Innoviz Technologies
NASDAQ:INVZ
|
-0.153x |
|
MDX Public Company Limited
BK:MDX
|
-0.013x |
|
Shin Tai Industry Co Ltd
TW:1235
|
0.002x |
|
RoboRobo Co. Ltd
KQ:215100
|
0.006x |
|
Bareket Capital Ltd
TA:BRKT
|
N/A |
Annual Cash Flow Conversion Efficiency for LeonaBio, Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of LeonaBio, Inc. from 2018 to 2025. Review financial flexibility index of LeonaBio, Inc. to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.79 Million | $-45.73 Million | -1.646x | +24.06% |
| 2024-12-31 | $44.84 Million | $-97.17 Million | -2.167x | -180.01% |
| 2023-12-31 | $130.19 Million | $-100.75 Million | -0.774x | -151.11% |
| 2022-12-31 | $235.14 Million | $-72.47 Million | -0.308x | -129.61% |
| 2021-12-31 | $321.08 Million | $-43.10 Million | -0.134x | -52.68% |
| 2020-12-31 | $274.28 Million | $-24.11 Million | -0.088x | -146.70% |
| 2019-12-31 | $-19.72 Million | $-3.71 Million | 0.188x | -37.48% |
| 2018-12-31 | $-14.89 Million | $-4.48 Million | 0.301x | -- |
About LeonaBio, Inc.
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment o… Read more